Effect of Osocimab in Preventing Venous Thromboemb
Undergoing Knee Arthroplasty: The FOXTROT Random

JAMA - Journal of the American Medical Association

323, 130-139

DOI: 10.1001/jama.2019.20687

Citation Report

#	Article	IF	Citations
1	Editorial Commentary: Preventing Venous Thromboembolism in Non-Major Orthopedic Surgery: Generalizing Recommendations for Heterogenous Patient Populations. Trends in Cardiovascular Medicine, 2021, 31, 512-514.	7.8	0
2	The Rebirth of the Contact Pathway: A New Therapeutic Target. Current Opinion in Hematology, 2020, 27, 311.	3.2	56
3	Pulmonary Embolism: Update on Management and Controversies. BMJ, The, 2020, 370, m2177.	11.6	206
4	Model-Dependent Contributions of FXII and FXI to Venous Thrombosis in Mice. Journal of Thrombosis and Haemostasis, 2020, 18, 2899-2909.	5.0	32
5	A Review of the Incidence Diagnosis and Treatment of Spontaneous Hemorrhage in Patients Treated With Direct Oral Anticoagulants. Journal of Clinical Medicine, 2020, 9, 2984.	3.8	40
6	Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia. ChemistryOpen, 2020, 9, 1161-1172.	3.0	20
7	Osocimab: A Novel Agent in Preventing Venous Thromboembolism. Journal of Cardiovascular Pharmacology, 2020, 76, 645.	2.5	17
8	Role of Factor XIa and Plasma Kallikrein in Arterial and Venous Thrombosis. Thrombosis and Haemostasis, 2020, 120, 883-993.	4.6	69
9	Therapeutic Strategies for Thrombosis: New Targets and Approaches. Nature Reviews Drug Discovery, 2020, 19, 333-352.	91.0	387
10	Surgical Venous Thromboembolism Prophylaxis: Clinical Practice Update. Hospital Practice (1995), 2020, 48, 248-257.	1.2	33
11	The Contact Activation System as a Potential Therapeutic Target in Patients With COVID-19. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 500-505.	3.3	35
12	Turning Up to Eleven: Factor XI Inhibitors as Novel Agents to Maximize Safety and Maintain Efficacy in Thromboembolic Disease. Current Problems in Cardiology, 2021, 46, 100696.	4.1	7
13	A Novel Rationale for Targeting FXI: Insights From the Hemostatic microRNA Targetome for Emerging Anticoagulant Strategies. Pharmacology & Therapeutics, 2021, 218, 107676.	14.1	11
14	New Anticoagulants: Moving Beyond the Direct Oral Anticoagulants. Journal of Thrombosis and Haemostasis, 2021, 19, 20-29.	5.0	72
15	The Intrinsic Pathway Does Not Contribute to Activation of Coagulation in Mice Bearing Human Pancreatic Tumors Expressing Tissue Factor. Thrombosis and Haemostasis, 2021, 121, 967-970.	4.6	5
16	Advances in the Management of Acute Venous Thromboembolism and New Therapeutic Agents. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 218-232.	3.4	5
17	Drugs in Phase I and II Clinical Development for the Prevention of Stroke in Patients With Atrial Fibrillation. Expert Opinion on Investigational Drugs, 2021, 30, 1057-1069.	4.4	13
18	Factor XI as a Target for New Anticoagulants. Hamostaseologie, 2021, 41, 104-110.	1.5	85

#	Article	IF	Citations
19	Improved Efficacy/Safety Profile of Factor XIa Inhibitor BMS-724296 Versus Factor Xa Inhibitor Apixaban and Thrombin Inhibitor Dabigatran in Cynomolgus Monkeys. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12524.	3.3	9
20	Optimal Tests to Minimise Bleeding and Ischaemic Complications in Patients on Extracorporeal Membrane Oxygenation. Thrombosis and Haemostasis, 2022, 122, 480-491.	4.6	33
21	Alternatives for Vitamin K Antagonists as Thromboprophylaxis for Mechanical Heart Valves and Mechanical Circulatory Support Devices: A Systematic Review. Seminars in Thrombosis and Hemostasis, 2021, 47, 724-734.	4.1	3
22	Antithrombotics and New Interventions for Venous Thromboembolism: Exploring Possibilities Beyond Factor IIa and Factor Xa Inhibition. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12509.	3.3	13
23	Submassive Pulmonary Embolism: Current Perspectives and Future Directions. Journal of Clinical Medicine, 2021, 10, 3383.	3.8	24
24	Venous Thromboembolism. Lancet, The, 2021, 398, 64-77.	96.9	715
25	First Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of BAY 2433334, a Small Molecule Targeting Coagulation Factor XIa. Journal of Thrombosis and Haemostasis, 2021, 19, 2407-2416.	5.0	91
26	Abelacimab for Prevention of Venous Thromboembolism. New England Journal of Medicine, 2021, 385, 609-617.	76.6	305
27	Factor XI Inhibition to Uncouple Thrombosis From Hemostasis: JACC Review Topic of the Week. Journal of the American College of Cardiology, 2021, 78, 625-631.	12.0	192
28	Factor XI Deficiency. Hematology/Oncology Clinics of North America, 2021, 35, 1157-1169.	3.1	96
29	Anticoagulation in Patients With Kidney Failure on Dialysis: Factor XI as a Therapeutic Target. Kidney International, 2021, 100, 1199-1207.	12.9	44
30	First-in-Human Study of Milvexian, an Oral, Direct, Small Molecule Factor XIa Inhibitor. Clinical and Translational Science, 2022, 15, 330-342.	4.1	98
31	ONO-7684 a Novel Oral FXIa Inhibitor: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in a First-in-Human Study. British Journal of Clinical Pharmacology, 2021, 87, 3177-3189.	3.0	38
32	Recent Advances in Understanding, Diagnosing and Treating Venous Thrombosis. F1000Research, 2020, 9, 1206.	1.1	12
33	Activated Factor XI Is Increased in Plasma in Response to Surgical Trauma but Not to Recombinant Activated FVII-Induced Thrombin Formation. Journal of Atherosclerosis and Thrombosis, 2022, 29, 82-98.	3.7	7
34	Pharmacokinetics and Pharmacodynamics of Abelacimab (MAA868), a Novel Dual Inhibitor of Factor XI and Factor XIa. Journal of Thrombosis and Haemostasis, 2022, 20, 307-315.	5.0	107
35	Multimodal Thromboprophylaxis in Patients With a History of Venous Thromboembolism Undergoing Primary and Revision Knee Arthroplasty. HSS Journal, 2022, 18, 212-218.	1.7	2
36	A Proposal for Managing Bleeding in Patients on Therapeutic Factor XI(a) Inhibitors. Journal of Thrombosis and Haemostasis, 2022, 20, 32-38.	5.0	43

#	Article	IF	Citations
37	Abelacimab for Prevention of Venous Thromboembolism. New England Journal of Medicine, 2021, 385, 1821.	76.6	2
38	Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD. Kidney International Reports, 2022, 7, 200-209.	4.5	93
39	Milvexian, an Orally Bioavailable, Small-Molecule, Reversible, Direct Inhibitor of Factor XIa: In Vitro Studies and in Vivo Evaluation in Experimental Thrombosis in Rabbits. Journal of Thrombosis and Haemostasis, 2022, 20, 399-408.	5.0	65
40	Milvexian for the Prevention of Venous Thromboembolism. New England Journal of Medicine, 2021, 385, 2161-2172.	76.6	270
41	Advances in Anticoagulation: Patients With Bioprosthetic Heart Valves. Cardiovascular Research, 2022, 118, e26-e28.	13.5	7
42	Can Targeting Factor XIa Dissociate Thrombosis From Haemostasis?. European Heart Journal, 2022, 43, 1031-1032.	14.7	2
43	Factor XI as a Target for Preventing Venous Thromboembolism. Journal of Thrombosis and Haemostasis, 2022, 20, 550-555.	5.0	14
44	Pharmacokinetics, Pharmacodynamics and Safety of BAY 2433334, a Novel Activated Factor XI Inhibitor, in Healthy Volunteers: A Randomized Phase 1 Multiple-Dose Study. British Journal of Clinical Pharmacology, 2022, 88, 3447-3462.	3.0	66
45	Pharmacological and Interventional Management of Pulmonary Embolism: Where Do We Stand?. Future Cardiology, 2022, 18, 191-206.	1.2	6
46	First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects. Frontiers in Pharmacology, 2022, 13, 821363.	5.3	21
47	Active FXI Can Independently Predict Ischemic Stroke in Anticoagulated Atrial Fibrillation Patients: A Cohort Study. Thrombosis and Haemostasis, 2022, 122, 1397-1406.	4.6	14
48	Pharmacological Profile of Asundexian, a Novel, Orally Bioavailable Inhibitor of Factor XIa. Journal of Thrombosis and Haemostasis, 2022, 20, 1400-1411.	5.0	115
49	Safety, Pharmacokinetics, and Pharmacodynamics of Milvexian in Healthy Japanese Participants. Scientific Reports, 2022, 12, 1-8.	5.2	23
50	Genetic Architecture of Stroke of Undetermined Source: Overlap With Known Stroke Etiologies and Associations With Modifiable Risk Factors. Annals of Neurology, 2022, 91, 640-651.	8.1	25
51	Safety of the Oral Factor XIa Inhibitor Asundexian Compared With Apixaban in Patients With Atrial Fibrillation (PACIFIC-AF): A Multicentre, Randomised, Double-Blind, Double-Dummy, Dose-Finding Phase 2 Study. Lancet, The, 2022, 399, 1383-1390.	96.9	317
52	Making Anticoagulation Safer. Lancet, The, 2022, 399, 1360-1361.	96.9	11
53	Incidence and Determinants of Thrombotic and Bleeding Complications in Patients With Glioblastoma. Journal of Thrombosis and Haemostasis, 2022, 20, 1665-1673.	5.0	36
54	A Commitment to Global Collaboration, Welcoming International Participation and Advancing Science for the Benefit of Patients. Bleeding, Thrombosis, and Vascular Biology, 2022, .	0.3	2

#	Article	IF	Citations
55	Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence. Frontiers in Cardiovascular Medicine, 2022, 9, 903029.	3.2	83
56	First Randomized Evaluation of Safety, Pharmacodynamics, and Pharmacokinetics of BAY 1831865, an Antibody Targeting Coagulation Factor XI and Factor XIa, in Healthy Men. Journal of Thrombosis and Haemostasis, 2022, 20, 1684-1695.	5.0	29
57	Factor XI Inhibition for the Prevention of Venous Thromboembolism: An Update on Current Evidence and Future Perspectives. Vascular Health and Risk Management, 2022, 18, 359-373.	3.7	30
58	A Novel Inhibitor of Factor XIa as Potential Haemostasis-Sparing Anticoagulant for Patients With Atrial Fibrillation. European Heart Journal, 2022, 43, 2354-2355.	14.7	4
59	Coagulation Factors XI and XII as Possible Targets for Anticoagulant Therapy. Thrombosis Research, 2022, 214, 53-62.	2.9	25
60	Anticoagulants: Dose Control Methods and Inhibitors. Obstetrics, Gynecology and Reproduction, 2022, 16, 158-175.	0.6	5
61	Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, a Factor XIa Inhibitor. Cardiology and Therapy, 2022, 11, 407-419.	3.6	23
62	Preparation, Characterization, and Pharmacokinetics of Rivaroxaban Cocrystals With Enhanced in Vitro and in Vivo Properties in Beagle Dogs. International Journal of Pharmaceutics: X, 2022, 4, 100119.	5.6	20
63	A Factor XIa Inhibitor Engineered From Banded Krait Venom Toxin: Efficacy and Safety in Rodent Models of Arterial and Venous Thrombosis. Biomedicines, 2022, 10, 1679.	4.9	5
64	Single-Dose Pharmacokinetics of Milvexian in Participants With Normal Renal Function and Participants With Moderate or Severe Renal Impairment. Clinical Pharmacokinetics, 2022, 61, 1405-1416.	4.0	29
65	Rationale and Design of the AXIOMATIC-SSP Phase II Trial: Antithrombotic Treatment With Factor XIa Inhibition to Optimize Management of Acute Thromboembolic Events for Secondary Stroke Prevention. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106742.	2.2	41
66	A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. Circulation, 2022, 146, 1196-1206.	24.6	165
67	Factor XIa Inhibition With Asundexian After Acute Non-Cardioembolic Ischaemic Stroke (PACIFIC-Stroke): An International, Randomised, Double-Blind, Placebo-Controlled, Phase 2b Trial. Lancet, The, 2022, 400, 997-1007.	96.9	217
68	Achieving Higher Efficacy Without Compromising Safety With Factor XI Inhibitors Versus Low Molecular Weight Heparin for the Prevention of Venous Thromboembolism in Major Orthopedic Surgery—Systematic Review and Meta-Analysis. Journal of Thrombosis and Haemostasis, 2022, 20, 2930-2938.	5.0	39
69	Current and Emerging Drug Strategies for the Prevention of Venous Thromboembolism in Acutely Ill Medical Inpatients. Expert Opinion on Pharmacotherapy, 2022, 23, 1651-1665.	3.5	3
70	Clinical Pharmacology of Factor XI Inhibitors: New Therapeutic Approaches for Prevention of Venous and Arterial Thrombotic Disorders. Journal of Clinical Medicine, 2022, 11, 6314.	3.8	31
71	SHR2285, The First Selectively Oral FXIa Inhibitor in China: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Combined With Aspirin, Clopidogrel or Ticagrelor. Frontiers in Pharmacology, 2022, 13, 1027627.	5.3	14
72	Factor XI, a Potential Target for Anticoagulation Therapy for Venous Thromboembolism. Frontiers in Cardiovascular Medicine, 2022, 9, 975767.	3.2	5

#	Article	IF	Citations
73	Properdin (Factor P) as a New Target Cleaved by Factor XIa: Intrinsic Coagulation at the Crossroads With Inflammation. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12835.	3.3	0
74	Novel Antithrombotic Agents in Ischemic Cardiovascular Disease: Progress in the Search for the Optimal Treatment. Journal of Cardiovascular Development and Disease, 2022, 9, 397.	2.9	15
75	Pharmacotherapy for Stroke Prevention in Nonvalvular Atrial Fibrillation: Current Strategies and Future Directions. Expert Opinion on Pharmacotherapy, 2022, 23, 1941-1955.	3.5	8
76	Risk of Venous Thromboembolism and Major Bleeding in the Clinical Course of Osteosarcoma and Ewing Sarcoma. Thrombosis Research, 2023, 221, 19-25.	2.9	10
77	Joint 2022 European Society of Thoracic Surgeons and the American Association for Thoracic Surgery Guidelines for the Prevention of Cancer-Associated Venous Thromboembolism in Thoracic Surgery. European Journal of Cardio-thoracic Surgery, 2022, .	2.2	24
78	Coming Soon to a Pharmacy Near You? FXI and FXII Inhibitors to Prevent or Treat Thromboembolism. Hematology, 2022, 2022, 495-505.	2.5	10
79	Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease. Journal of Cardiovascular Development and Disease, 2022, 9, 437.	2.9	20
80	Joint 2022 European Society of Thoracic Surgeons and the American Association for Thoracic Surgery Guidelines for the Prevention of Cancer-Associated Venous Thromboembolism in Thoracic Surgery. Journal of Thoracic and Cardiovascular Surgery, 2023, 165, 794-824.e6.	3.6	18
81	Effects of Tablet Formulation, Food, or Gastric pH on the Bioavailability of Asundexian. Clinical Pharmacology in Drug Development, 2023, 12, 219-230.	1.8	14
82	Efficacy of 11 Anticoagulants for the Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty: A Systematic Review and Network Meta-Analysis. Medicine (United States), 2023, 102, e32635.	2.1	7
83	Platelet–Neutrophil Crosstalk in Thrombosis. International Journal of Molecular Sciences, 2023, 24, 1266.	5.9	63
84	Titanium Is a Potent Inducer of Contact Activation: Implications for Intravascular Devices. Journal of Thrombosis and Haemostasis, 2023, 21, 1200-1213.	5.0	17
85	Factor XI Inhibitors: What Should Clinicians Know. Current Opinion in Cardiology, 2023, 38, 88.	2.2	5
86	Fluorescent Activity-Based Probe to Image and Inhibit Factor XIa Activity in Human Plasma. Journal of Medicinal Chemistry, 2023, 66, 3785-3797.	7.4	6
87	Pharmacology and Clinical Development of Factor XI Inhibitors. Circulation, 2023, 147, 897-913.	24.6	147
88	Factor XIa Inhibitors in Anticoagulation Therapy: Recent Advances and Perspectives. Journal of Medicinal Chemistry, 2023, 66, 5332-5363.	7.4	30
89	BJTJ-1837, a Novel FXI Activation-Blocking Antibody. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100067.	3.3	4
90	A Review of FXIa Inhibition as a Novel Target for Anticoagulation. Hamostaseologie, 2023, 43, 028-036.	1.5	26

#	Article	IF	Citations
91	Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week. Journal of the American College of Cardiology, 2023, 81, 771-779.	12.0	81
92	Factor XI Inhibitors in Early Clinical Trials: A Meta-Analysis. Thrombosis and Haemostasis, 2023, 123, 576-584.	4.6	62
93	A Review of Emerging Factor XI Inhibitors. Expert Opinion on Emerging Drugs, 2023, 28, 43-53.	3.8	6
94	BMS-262084, a FXIa Inhibitor, Interferes With Tumor Cell-Induced Coagulation Activation Only in Tumor Cells With Low Tissue Factor (TF) Procoagulant Activity (PCA). Hamostaseologie, 2023, 43, T-06-02.	1.5	0
95	Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis. TH Open, 2023, 07, e97-e104.	1.8	6
96	Reversal Agents for Current and Forthcoming Direct Oral Anticoagulants. European Heart Journal, 2023, 44, 1795-1806.	14.7	55
97	Predictive Value for Increased Activated Factor XI Activity in Acute Venous Thromboembolism. Journal of Thrombosis and Haemostasis, 2023, 21, 1610-1622.	5.0	13
98	High Plasma Levels of C1-Inhibitor Are Associated With Lower Risk of Future Venous Thromboembolism. Journal of Thrombosis and Haemostasis, 2023, 21, 1849-1860.	5.0	20
99	News at XI: Moving Beyond Factor Xa Inhibitors. Journal of Thrombosis and Haemostasis, 2023, 21, 1692-1702.	5.0	60
100	Potential Anticoagulant of Traditional Chinese Medicine and Novel Targets for Anticoagulant Drugs. Phytomedicine, 2023, 116, 154880.	11.1	25
101	Updates in the Incidence, Pathogenesis, and Management of Cancer and Venous Thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2023, 43, 824-831.	7.9	79
102	Management of Intracranial Hemorrhage in the Setting of Mechanical Heart Valve Replacement Therapy. Applied Mechanics, 2023, 4, 644-667.	1.8	3
103	Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction. Oncologist, 2023, 28, 555-564.	5.0	38
104	New Pharmacotherapeutic Options for Oral Anticoagulant Treatment in Atrial Fibrillation Patients Aged 65 and Older: Factor XIa Inhibitors and Beyond. Expert Opinion on Pharmacotherapy, 2023, 24, 1335-1347.	3.5	3
105	A Commitment to Global Collaboration, Welcoming International Participation and Advancing Science for the Benefit of Patients. Bleeding, Thrombosis, and Vascular Biology, 2023, .	0.3	3
106	Factor XIa Inhibitors as a Novel Anticoagulation Target: Recent Clinical Research Advances. Pharmaceuticals, 2023, 16, 866.	6.1	21
107	The Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, an Oral Small Molecule Factor XIa Inhibitor, in Healthy Chinese Volunteers. Clinical Drug Investigation, 2023, 43, 435-445.	3.1	6
108	ThromboprophylaXIs With Factor XI/XIa Inhibitors for Venous Thromboembolism. Jornal Vascular Brasileiro, 2023, 22, e20230051.	1.0	2

#	Article	IF	Citations
109	An Update on Novel Therapies for Treating Patients With Arterial Thrombosis. Expert Review of Hematology, 2023, 16, 593-605.	2.7	6
110	Development of New Anticoagulant in 2023: Prime Time for Anti-Factor XI and XIa Inhibitors. JMV-Journal De Medecine Vasculaire, 2023, 48, 69-80.	1.2	39
111	Indefinite Anticoagulant Therapy for First Unprovoked Venous Thromboembolism. Annals of Internal Medicine, 2023, 176, 949-960.	12.9	14
112	Anticoagulant Therapy for Mechanical Heart Valves — Unmet Need Persists. NEJM Evidence, 2023, 2, EVIDe2300106.	10.7	0
113	Recent Progress in Factor XI/XIa Inhibitor Discovery. Medicinal Chemistry Reviews, 2022, .	0.3	0
114	A New Strategy for Anticoagulation: The Factor XI Inhibitors. European Journal of Internal Medicine, 2023, 116, 8-15.	4.2	20
115	Venous Thromboembolism Prophylaxis in Major Orthopedic Surgeries and Factor XIa Inhibitors. Medical Sciences, 2023, 11, 49.	6.3	42
116	Research and Clinical Approaches to Assess Platelet Function in Flowing Blood. Arteriosclerosis, Thrombosis, and Vascular Biology, 2023, 43, 1775-1783.	7.9	12
117	Efficacy and Safety of Oral Factor XIa Inhibitors in Stroke Prevention: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2023, 12, 5562.	3.8	17
118	New Therapeutic Targets for the Prevention and Treatment of Venous Thromboembolism With a Focus on Factor XI Inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2023, 43, 1755-1763.	7.9	32
119	Design and Preclinical Characterization Program Toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders. Journal of Medicinal Chemistry, 2023, 66, 12203-12224.	7.4	35
120	Next Generation Anticoagulants: A Spotlight on the Potential Role of Activated Factors XII and XI. Expert Review of Hematology, 2023, 16, 711-714.	2.7	2
121	Factor XI Inhibitors for the Prevention of Cardiovascular Disease: A New Therapeutic Approach on the Horizon?. Blood Reviews, 2023, 62, 101119.	7.6	8
122	Inhibition of Factor XI: A New Era in the Treatment of Venous Thromboembolism in Cancer Patients?. International Journal of Molecular Sciences, 2023, 24, 14433.	5.9	12
123	Effect of Factor XI Inhibition on Tumor Cell-Induced Coagulation Activation. Journal of Thrombosis and Haemostasis, 2024, 22, 199-212.	5.0	14
124	An Updated Systematic Review and Meta-Analysis of the Impact of Graduated Compression Stockings in Addition to Pharmacological Thromboprophylaxis for Prevention of Venous Thromboembolism in Surgical Inpatients. Annals of Surgery, 2024, 279, 29.	6.7	20
125	Anticoagulation in Chronic Kidney Disease: Current Status and Future Perspectives. Journal of Thrombosis and Haemostasis, 2024, 22, 323-336.	5.0	53
126	Outcome of Preventive Nursing Intervention, Prophylactic Anticoagulation and the Use of the Caprini Score on Venous Thromboembolism After Varicose Vein Surgery. African Health Sciences, 2023, 23, 616-623..	1.0	2

#	Article	IF	Citations
127	Inhibidores del factor XI: una nueva era en el tratamiento antitrombótico. Medicina Clínica, 2024, 162, 73-76.	1.2	4
128	Novel Strategies in Antithrombotic Therapy: Targeting Thrombosis While Preserving Hemostasis. Frontiers in Cardiovascular Medicine, 2023, 10, 1272971.	3.2	26
129	Factor XI in Carriers of Antiphospholipid Antibodies: Elevated Levels Associated With Symptomatic Thrombotic Cases, While Low Levels Linked to Asymptomatic Cases. International Journal of Molecular Sciences, 2023, 24, 16270.	5.9	2
130	Factor XI/XIa Inhibitors for the Prevention and Treatment of Venous and Arterial Thromboembolism: A Narrative Review. Vascular Medicine, 2024, 29, 85-92.	2.3	20
131	Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Undergoing Central Line Placement: A Phase 2 Clinical Trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 2024, 44, 290-299.	7.9	54
132	Safety and Efficacy of Factor XIa Inhibition With Milvexian for Secondary Stroke Prevention (AXIOMATIC-SSP): A Phase 2, International, Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Trial. Lancet Neurology, The, 2024, 23, 46-59.	43.7	121
133	Factor XI/XIa Inhibitors: A New Approach to Anticoagulation. Cardiology in Review, 2025, 33, 10.1097/CRD.0000000000000624.	1.7	3
134	Reshaping Anticoagulation: Factor XI Inhibition in Thrombosis Management. Hamostaseologie, 2024, 44, 049-058.	1.5	7
135	Targeting Factor XI and Factor XIa to Prevent Thrombosis. Blood, 2024, 143, 1465-1475.	10.6	69
136	Factor XI Inhibitors: A New Era in Antithrombotic Therapy. Medicina Clínica (English Edition), 2024, 162, 73-76.	0.2	0
137	Pharmacological and Clinical Appraisal of Factor XI Inhibitor Drugs. European Heart Journal - Cardiovascular Pharmacotherapy, 2024, 10, 245-258.	5.0	31
138	Factor XI Inhibitors: Potential Role in End-Stage Kidney Disease. Seminars in Nephrology, 2023, 43, 151484.	3.1	7
139	Factor XI Inhibitors: A New Horizon in Anticoagulation Therapy. Cardiology and Therapy, 2024, 13, 1-16.	3.6	24
140	Systematic Review of Clinical Trials on Antithrombotic Therapy With Factor XI Inhibitors. Revista Clínica Española, 2024, 224, 167-177.	1.1	4
141	Milvexian: A Focus on a New Oral Anticoagulant That Targets Factor XIa for Thromboembolism Prophylaxis. Cardiology in Review, 2025, 33, 10.1097/CRD.0000000000000588.	1.7	2
142	Anticoagulation With Osocimab in Patients With Kidney Failure Undergoing Hemodialysis: A Randomized Phase 2 Trial. Nature Medicine, 2024, 30, 435-442.	51.2	59
143	Revisión sistemática de los ensayos clínicos sobre terapia antitrombótica con inhibidores del factor XI. Revista Clinica Espanola, 2024, 224, 167-177.	0.3	1
144	Endogenously Produced Factor XI (FXI) Contributes to Hepatic Cancer Cell-Induced Coagulation Activation. Hamostaseologie, 2024, 44, T-06-09.	1.5	0

#	Article	IF	Citations
145	Reducing the Global Burden of Cerebral Venous Thrombosis: An International Research Agenda. International Journal of Stroke, 2024, 19, 599-610.	7.4	19
146	Drug–Drug Interactions of FXI Inhibitors: Clinical Relevance. Hematology Reports, 2024, 16, 151-163.	2.2	14
147	A Phase II Randomized Controlled Trial Evaluated Antithrombotic Treatment With Fesomersen in Patients With Kidney Failure on Hemodialysis. Kidney International, 2024, 106, 145-153.	12.9	42
148	Pharmacokinetics, Pharmacodynamics, and Safety of Frunexian in Healthy Chinese Volunteer Adults: A Randomized Dose-Escalation Phase I Study. Clinical and Translational Science, 2024, 17, e13787.	4.1	9
149	Advances and Current Research in Primary Thromboprophylaxis to Prevent Hospital-Associated Venous Thromboembolism. British Journal of Haematology, 2024, 204, 1635-1648.	3.2	4
150	The Current Landscape of Factor XI Inhibitors. Thrombosis Update, 2024, 15, 100171.	1.6	5
151	Faktor-XI-Hemmer - neue Therapeutika in der Prävention von Thromboembolien. InFo Neurologie & Psychiatrie, 2024, 26, 44-53.	0.0	1
152	Osocimab zur antithrombotischen Therapie bei Patienten mit chronischer Nierenerkrankung. Die Nephrologie, 2024, 19, 241-243.	0.1	0
153	The Foundation for Investigating Factor XI as a Target for Inhibition in Human Cardiovascular Disease. Journal of Thrombosis and Thrombolysis, 2024, 57, 1283-1296.	2.2	9
154	Factor XI Inhibitors: A New Option for the Prevention and Treatment of Cancer-Associated Thrombosis. Bleeding, Thrombosis, and Vascular Biology, 2024, .	0.3	0
155	Factor XI as a New Target for Prevention of Thromboembolism in Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials. Journal of Thrombosis and Thrombolysis, 2025, 58, 1-14.	2.2	12
156	Novel Horizons in Anticoagulation: The Emerging Role of Factor XI Inhibitors Across Different Settings. Haematologica, 2024, 109, 3110-3124.	3.9	18
157	Factor XI and XIa Inhibition: A New Approach to Anticoagulant Therapy. British Journal of Cardiology, 2024, 31, 018.	0.6	9
158	Future of Factor XI Inhibitors in Cardiovascular Practice. Minerva Cardiology and Angiology, 2025, 73, 201-218.	1.3	7
159	Inhibice koagulačního faktoru XI/XIa - další krok ve zvýšení bezpečnosti antikoagulační léčby?. Vnitrni Lekarstvi, 2024, 70, 213-218.	0.2	0
160	Pharmacotherapy for Venous Thromboprophylaxis Following Total Hip or Knee Arthroplasty: A Systematic Review and Network Meta-Analysis. Seminars in Thrombosis and Hemostasis, 2025, 51, 290-300.	4.1	6
161	There Is Still No Alternative to Warfarin for Mechanical Valves: It Remains the Most Effective Anticoagulant. Journal of Thoracic and Cardiovascular Surgery, 2025, 0, 489-494.	3.6	9
162	Will Factor XI Inhibitors Replace Current Anticoagulants for Stroke Prevention in Atrial Fibrillation?. Current Cardiology Reports, 2024, 26, 1-7.	4.5	8

#	Article	IF	Citations
163	Anticoagulant Therapy in Renal Insufficiency Theme: Anticoagulation in Complex Situations. Thrombosis Research, 2024, 241, 109097.	2.9	3
164	Factor XI Inhibitors – Rising Stars in Anti-Thrombotic Therapy?. Journal of the Neurological Sciences, 2024, 464, 123157.	2.7	17
165	Therapeutic Potential of FXI Inhibitors: Hype or Hope?. Drugs, 2024, 84, 1055-1070.	15.5	19
166	Factor XIa Inhibition as a Therapeutic Strategy for Atherothrombosis. Journal of Thrombosis and Thrombolysis, 2024, 57, 1297-1307.	2.2	10
167	Regulation of Platelet Activation and Coagulation: Current Concepts, Novel Targets, and Therapies. Interventional Cardiology Clinics, 2024, 13, 451-467.	1.1	1
168	The First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Factor XI Monoclonal Antibody SHR-2004 in Healthy Subjects. Expert Opinion on Investigational Drugs, 2024, 33, 1075-1082.	4.4	6
169	Milvexian: An Oral, Bioavailable Factor XIa Inhibitor. Cardiology and Therapy, 2024, 13, 1-17.	3.6	5
170	Milvexian vs Apixaban for Stroke Prevention in Atrial Fibrillation: The LIBREXIA Atrial Fibrillation Trial Rationale and Design. American Heart Journal, 2024, 277, 145-158.	3.3	49
171	Incidence and Impact on Quality of Life of Heavy Menstrual Bleeding in Women on Oral Anticoagulant Therapy. Clinical and Applied Thrombosis/Hemostasis, 2024, 30, 10760296241281366.	2.2	4
172	Catheter-Related Deep Vein Thrombosis: Where Are We at and Where Are We Going? Updates and Ongoing Unmet Clinical Needs. European Journal of Clinical Investigation, 2025, 55, e14311.	4.4	23
173	Pharmacokinetics and Pharmacodynamics of the Factor XIa-Inhibiting Antibody Osocimab in Healthy Male East Asian Volunteers: Results From Two Phase 1 Studies. Pharmacology Research and Perspectives, 2024, 12, e70012.	2.8	7
174	Breaking Boundaries: Exploring Recent Advances in Anticoagulation and Thrombosis Management: A Comprehensive Review. Annals of Medicine and Surgery, 2024, 86, 10.1097/MS9.0000000000002589.	1.7	3
175	The Third-Generation Anticoagulants: Factors XI, XII, and XIII Inhibitors. Egyptian Heart Journal, 2024, 76, 1-11.	1.8	7
176	A Systematic Review of Safety and Efficacy of Factor XI/XIa Inhibitors in Patients With ESKD on Hemodialysis. Kidney International Reports, 2025, 10, 145-156.	4.5	12
177	Factor XI/XIa Inhibitors: What We Now Know. EMJ Cardiology, 2024, 12, 2-13.	0.2	0
178	Faktor-XI-Hemmer - neue Therapeutika in der Prävention von Thromboembolien. CardioVasc, 2024, 24, 40-51.	0.0	0
179	Déjà vu all over again: a recurrent flaw in anticoagulant study design. Journal of Thrombosis and Haemostasis, 2025, 23, 23-26.	5.0	3
180	From the INVICTUS Trial to Current Considerations: It's Not Time to Retire Vitamin K Inhibitors Yet!. Pharmaceuticals, 2024, 17, 1459.	6.1	3

#	Article	IF	Citations
181	Advancements in Serine Protease Inhibitors: From Mechanistic Insights to Clinical Applications. Catalysts, 2024, 14, 787.	4.7	36
182	The Factor XI/XIa Antibody Abelacimab Combined With Enoxaparin Inhibits Filter Clotting in Hemodialysis Circuits Ex Vivo. Journal of Thrombosis and Thrombolysis, 2024, 57, 1339-1348.	2.2	3
183	New Targets for Antithrombotic Medications: Seeking to Decouple Thrombosis From Hemostasis. Journal of Thrombosis and Haemostasis, 2025, 0, 1146-1159.	5.0	22
184	The Effect of Rivaroxaban as an Anticoagulant Therapy for Acute Pulmonary Embolism and the Predictive Role of Vascular Endothelial Markers in Assessing Anticoagulant Efficacy Before Treatment. American Journal of Translational Research (discontinued), 2025, 17, 294-307.	1.5	1
185	Selected Updates in Anti-Arrhythmic Drug Therapy and Anticoagulants: 2024. Journal of Innovations in Cardiac Rhythm Management, 2025, 16, 6144-6150.	1.0	1
186	Solid Tumors, Liquid Challenges: The Impact of Coagulation Disorders. Hematology Reports, 2025, 17, 8.	2.2	2
187	Direct Factor Xa Inhibitors Versus Low Molecular Weight Heparins or Vitamin K Antagonists for Prevention of Venous Thromboembolism in Elective Primary Hip or Knee Replacement or Hip Fracture Repair. Cochrane Database of Systematic Reviews, 2025, 1, CD011762.	6.9	6
188	Potential New Treatments for Chronic Kidney Diseases: A Concise Review. Current Pharmaceutical Design, 2025, 31, 1990-1997.	3.4	1
189	Development of New Anticoagulants Targeting Coagulation Factor XI and Prospects for Clinical Use. Journal of Cardiology, 2025, 85, 473-479.	3.8	8
190	Compassionate Use of Osocimab in Preventing Thrombotic Complications Without Incremental Bleeding: A Case Report. Hamostaseologie, 2025, 45, T-02-11.	1.5	1
191	Tapping Into the Natural PZ-Independent Anticoagulant Function of ZPI to Inhibit Thrombosis With Minimal Effect on Hemostasis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2025, 45, 805-819.	7.9	2
192	Factor XI and XII Inhibitors—Dawn of a New Era. Indian Heart Journal, 2025, 77, 122-129.	2.3	5
193	Recent Pathophysiological Insights Are Advancing the Treatment of Venous Thromboembolism. JACC Basic To Translational Science, 2025, 10, 689-703.	4.6	13
194	Discovery of the Low-Hemorrhagic Antithrombotic Effect of Montelukast by Targeting FXIa in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2025, 45, e150-e162.	7.9	5
195	Factor XI Localization in Human Deep Venous Thrombus and Function of Activated Factor XI on Venous Thrombus Formation and Hemostasis. Research and Practice in Thrombosis and Haemostasis, 2025, 9, 102720.	3.3	3
196	Activated Factor XI–Antithrombin and Thrombin–Antithrombin Complexes in the Prediction of Venous Thromboembolism and Mortality in Patients With Non–Small-Cell Lung Cancer. Journal of Thrombosis and Haemostasis, 2025, 23, 1908-1919.	5.0	8
197	Emerging Targets, Novel Directions, and Innovative Approaches in Thrombosis Therapy. Aging and disease, 2025, 17, 812-848.	7.1	4
198	Factor XI Inhibitors for the Prevention and Treatment of Venous and Arterial Thromboembolism. Nature Reviews Cardiology, 2025, 22, 896-912.	62.4	52

#	Article	IF	Citations
199	Contact Phase Inhibitors: The Future of Anticoagulation?. Journal of Laboratory Medicine, 2025, 49, 97-106.	2.2	1
200	Factor XI as a Drug Target for the Prevention and Treatment of Thrombosis. Journal of Cardiovascular Pharmacology, 2025, 86, 1.	2.5	0
201	Compassionate Use of Osocimab in Preventing Thrombotic Complications Without Incremental Bleeding: A Case Report. TH Open, 2025, 09, a25774474.	1.8	0
202	Tissue Factor, Factor VIII and IX in Microvesicle-Induced Thrombosis and Tumor Growth of Pancreatic Cancer. Thrombosis Journal, 2025, 23, 1-12.	2.9	6
203	Targeting Factor XI as a Compromise Between Thrombosis and Bleeding. Cardiology Journal, 2025, 32, 666-677.	1.7	1
204	Factor XI/XIa Inhibitors Versus Direct Oral Anticoagulants in Atrial Fibrillation With Stroke Risk: A GRADE-Assessed Meta-Analysis of Randomized Controlled Trials. Naunyn-Schmiedeberg's Archives of Pharmacology, 2025, 398, 14603-14616.	4.7	7
205	Anticoagulation in Atrial Fibrillation: Is a Paradigm Shift From Xa to XIa Inhibitors on the Horizon?. Cardiology in Review, 2025, .	1.7	0
206	Factor XI Inhibitors Are the Novel Promising Anticoagulants in the Treatment of Age Related Thrombotic Disease. Frontiers in Cardiovascular Medicine, 2025, 12, 1498826.	3.2	4
207	New Horizons in the Pharmacological Management of Venous Thromboembolism. HemaSphere, 2025, 9, e70143.	3.9	2
208	Factor XI Inhibitors: Is It Time for a Paradigm Shift in Anticoagulation?. Journal of Cardiovascular Medicine, 2025, 26, 303.	2.3	0
209	Long-Acting Factor XI Inhibition and Periprocedural Bleeding: An Analysis From AZALEA-TIMI 71. Journal of the American College of Cardiology, 2025, 85, 2288-2298.	12.0	16
210	Oral Anticoagulant Management for Peripheral Vascular Disease. Advances in Surgery, 2025, 59, 161-199.	2.1	0
211	The Factor XIa Antibody Osocimab Strongly Inhibits Clotting in Extracorporeal Circuits With Human Blood and in Baboons. Research and Practice in Thrombosis and Haemostasis, 2025, 9, 102932.	3.3	6
212	Effect of Heparins, Direct Oral Anticoagulants, and Factor XII/Factor XI Inhibitors on Catheter-Initiated Thrombin Generation in Platelet-Rich Plasma: An in Vitro Study. Journal of Thrombosis and Haemostasis, 2025, 23, 3173-3184.	5.0	9
213	Emerging Trends in Anticoagulation Therapy: A Bibliometric Analysis of DOACs and Endogenous Coagulation Pathway Inhibitors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2025, 398, 1-19.	4.7	1
214	The Safety and Efficacy of Factor XIa Inhibitors for the Prevention of Stroke and Thromboembolism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Stroke and Cerebrovascular Diseases, 2025, 34, 108381.	2.2	5
215	Venous Thromboembolism Prevention and Treatment With Factor XI/XIa Inhibitors: Current Status and Future Perspectives. Journal of Thrombosis and Thrombolysis, 2026, 59, 1-12.	2.2	4
216	Venous Thromboembolism in Patients With Cancer and Factor XI Deficiency. Journal of Thrombosis and Haemostasis, 2025, 23, 3286-3294.	5.0	2

#	Article	IF	Citations
217	The Discovery of a Novel Anticoagulant Mechanism: Factor XI Activation Inhibitors. ACS Pharmacology and Translational Science, 2025, 8, 3090-3100.	4.3	1
218	Quantitative Model-Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation. Clinical Pharmacology and Therapeutics, 2026, 119, 139-146.	5.3	5
219	Factor XI and Cancer: Physiopathological Linkage and Clinical Perspectives. Journal of Clinical Medicine, 2025, 14, 6341.	3.8	5
220	The Fibrinolytic System in Disease: From Molecular Pathways to Clinical Outcomes. Thrombosis Research, 2025, 256, 109504.	2.9	8
221	Next-Generation Anticoagulants: Precision Strategies for Patient-Centered Thromboprophylaxis. Journal of Personalized Medicine, 2025, 15, 490.	3.9	5
222	Efficacy and Safety of REGN9933A2 and REGN7508Cat for Preventing Postoperative Venous Thromboembolism (ROXI-VTE-I and ROXI-VTE-II): Two Randomised, Open-Label, Phase 2 Trials. Lancet, The, 2025, 406, 2551-2563.	96.9	21
223	Safety and Optimal Use of Direct Oral Anticoagulant Therapy. Expert Opinion on Drug Safety, 2026, 25, 1011-1030.	3.2	1
224	Cardiovascular Therapeutics at the Crossroads: Pharmacological, Genetic, and Digital Frontiers. Pharmaceuticals, 2025, 18, 1703.	6.1	2
225	Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic/Cardiovascular Events. CPT: Pharmacometrics and Systems Pharmacology, 2026, 15, e70142.	3.0	1
226	Oh's Intensive Care Manual. , 2026, .		5
227	New Horizons in Venous Thromboembolism Management: A Narrative Review. Journal of Clinical Medicine, 2025, 14, 7668.	3.8	3
228	Novel and Experimental Anticoagulant Strategies Beyond Current Direct Oral Anticoagulants. Journal of Thrombosis and Haemostasis, 2026, 24, 1213-1229.	5.0	7
229	Perioperative Management of Patients Receiving Factor XI Inhibitors. Thrombosis and Haemostasis, 2026, .	4.6	3
230	Targeting Factor XI for Safer Anticoagulation: Emerging Data and Future Directions. American Journal of Cardiovascular Drugs, 2026, 26, 1-17.	3.7	4
231	An Overview of Anticoagulant Drugs Pharmacology, Therapeutic Approaches, Limitations and Perspectives. Pharmaceutics, 2026, 18, 163.	7.5	3
232	Factor XI Inhibitors Versus Direct Oral Anticoagulants for the Prevention of Thromboembolic Events and Safety in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Heart and Lung: Journal of Acute and Critical Care, 2026, 78, 102739.	2.8	5
233	Targeting Factor XI for Venous Thromboembolism Prevention: A Tale of 2 Antibodies. Journal of Thrombosis and Haemostasis, 2026, 24, 1946-1948.	5.0	0
234	From Physiology to Clinical Practice in Pancreatic Cancer-Related Thromboembolism—A Review. Cancers, 2026, 18, 890.	5.3	1

#	Article	IF	Citations
235	Antithrombotic Therapy for Noncardioembolic Ischemic Stroke: Current Evidence and Future Directions. Stroke, 2026, 57, 1439-1449.	9.1	5
236	Pharmacologic Factor XI/XIa Inhibitors: What the Laboratory Hematologist Needs to Know. Clinics in Laboratory Medicine, 2026, 46, 243-258.	1.9	2
237	Pharmacological Management of Thrombosis: Current State and Future Strategies. International Journal of Molecular Sciences, 2026, 27, 3151.	5.9	2
238	Thrombophilia Work-Up and Clinical Outcomes in Indian Patients With Unprovoked Venous and Arterial Thrombosis Aged 18-50 Years. Bleeding, Thrombosis, and Vascular Biology, 2026, 5, 1-8.	0.3	0
239	Anticoagulation Challenges in Cancer Patients: Prevention, Detection, and Treatment Strategies. Cardio-Oncology, 2026, 12, 74.	5.3	0
240	Measuring Up: The Need for New Assays for Factor (F)XI/FXIa Inhibitor Therapies. Research and Practice in Thrombosis and Haemostasis, 2026, 10, 106640.	3.3	1
241	Chemical Synthesis and Biochemical Evaluation of Decasulfated Galloyl-Glucopyranose Heparin Mimetic. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2026, 24, 210-217.	1.5	0
242	Emerging Strategies in Venous Thromboembolism: A Narrative Review of Pharmacological Innovations. Thrombosis Journal, 2026, 24, 74.	2.9	0
243	Factor XI and XIa Inhibitors for Venous Thromboembolism Prophylaxis After Total Knee Arthroplasty: A Review From Mechanism to Phase III Trials. Journal of Arthroplasty, 2026, 41, 2688-2696.	4.7	0
244	Anticoagulation With the Mechanistically Distinct FXI/FXIa Antibodies Amrecibart (REGN9933A2) and Cenvacibart (REGN7508Cat). Blood, 2026, 148, 1867-1879.	10.6	2
245	Should We Focus on Sustainable Thromboprophylaxis and Avoid Overuse of Low-Molecular-Weight Heparins?. Research and Practice in Thrombosis and Haemostasis, 2026, 10, 106794.	3.3	0
246	Vers une médecine vasculaire intégrée, personnalisée et augmentée. Soins; La Revue De Reference Infirmiere, 2026, 71, 50-51.	0.1	0
247	Evaluating the Potential of Factor XI/Factor XIa Inhibitors to Address Unmet Anticoagulation Needs in Critical Patient Populations. Research and Practice in Thrombosis and Haemostasis, 2026, 10, 106624.	3.3	1
248	Factor XI Inhibition: Adult Evidence and Paediatric Considerations. Hamostaseologie, 2026, .	1.5	0
249	Factor XI Inhibition for Ischemic Stroke Secondary Prevention: Pharmacology, Clinical Evidence, and Future Directions. Journal of Clinical Pharmacology, 2026, 66, e70266.	2.4	0
250	Update on the Cardiovascular Application of Targeting Factor XI. Vessel Plus, 2026, 10, N/A.	0.7	0
251	Structural Insights Into the Exosite-Mediated Activation of Factor IX by Factor XIa Using Cryogenic Electron Microscopy. Journal of Thrombosis and Haemostasis, 2026, .	5.0	0
252	Perspectives: What We Are Learning From Factor XI/Factor XIa Inhibitor Trials. Research and Practice in Thrombosis and Haemostasis, 2026, 10, 106936.	3.3	0

#	Article	IF	Citations
253	Factor XI(a) Inhibition in Secondary Stroke Prevention: On the Cusp of a New Anticoagulation Paradigm. ACS Pharmacology and Translational Science, 2026, 9, 2675-2687.	4.3	0
254	Perioperative Management of Patients on Factor XI or Factor XIa Inhibitors. Journal of Thrombosis and Haemostasis, 2026, .	5.0	1
255	Factor XI and XIa Inhibitors: A State-of-the-Art Review Across Clinical Indications. Journal of Clinical Medicine, 2026, 15, 7431.	3.8	0
256	Beyond Traditional Anticoagulants: Exploring the Future of Thromboembolism Treatment With FXI Inhibitors. Frontiers in Immunology, 2026, 17, 1925585.	6.9	0
257	Deep Learning-Guided High-Throughput Screening and Molecular Dynamics Simulations Facilitate the Discovery of Potential FXIIa Inhibitors. Journal of Molecular Modeling, 2026, 32, 397.	3.0	0
258	Safety and Efficacy of Asundexian in Cardiovascular Diseases, Updated Systemic Review and Meta Analysis. Clinical and Applied Thrombosis/Hemostasis, 2026, .	2.2	0
259	Targeting Coagulation Factor XI/XIa for Anticoagulation Therapy: From Mechanism to Drug Development. Biochemical Pharmacology, 2026, .	6.7	0